ResultsIQ › Latest results › Accretion Nutraveda Ltd
Accretion Nutraveda Ltd Q2 FY27 results deck summary
NSE: ANL · BSE: 544694
Results deck of 3 Nov 2026, summarised by AI from the filing.
The company gives no numeric guidance; it only aims to expand capacity, add machinery and automation and use IPO proceeds per stated objects.
Key takeaways
- No numeric guidance The company gives no numeric guidance; it only aims to expand capacity, add machinery and automation and use IPO proceeds per stated objects.
- Margin dip EBITDA margin was 21.27% in H1 FY27 against 23.67% in H1 FY26, a decline of 241 bps, even as revenue more than doubled.
- Demand driver Revenue growth is attributed to increased demand for healthcare products, a diversified product portfolio and wider market reach.
- Raw material cost Raw materials of ₹21.68 cr in H1 FY27 were the largest cost, and the presentation gives no outlook on input costs.
Accretion Nutraveda Ltd earnings call, investor presentation and press release summaries
- Q2 FY27: Results deck (3 Nov 2026)
Figures from the company's filings with NSE and BSE. Not investment advice.